FORMULATION AND EVALUATION OF BI-LAYERED TABLET OF ATENOLOL AND HYDROCHLOROTHIAZIDE

The study focuses on creating and evaluating a specialized bilayer tablet for treating hypertension. It begins with in-depth preformulation analyses of key components like Atenolol, Hydrochlorothiazide, and various excipients. Special emphasis is placed on optimizing the powder blend’s flow properties to facilitate tablet compression. A series of tests on resulting tablets (F1 to F8) assess weight variation, thickness, hardness, friability, disintegration time, and drug content, ensuring they meet required specifications with uniform weight and hardness. Dissolution profiles of all formulations are examined, with Formulation 8 (F8) identified as the most suitable for consistent drug release across both layers. The study investigates drug release mechanisms, finding that both layers adhere to the diffusion-controlled release model, particularly the Higuchi model. Stability tests conducted under elevated temperature and humidity (40°C/75% RH) over three months reveal minimal changes in physical attributes, drug content, and drug release profiles, confirming the tablet’s stability. In conclusion, the study successfully develops an optimized Immediate Release Bilayer Tablet containing Atenolol and Hydrochlorothiazide. This tablet offers controlled and uniform drug release, vital for managing hypertension. Importantly, the tablet formulation maintains stability over three months. Future research and clinical evaluations are recommended to establish the efficacy and safety of this optimized bilayer tablet for hypertensive patients.